Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study

The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV1) in patients with chronic obstructive pulmonary disease (COPD) has rarely been investigated. Using CRYSTAL, a 12-week open-label study in symptomatic, nonfrequently exace...

Full description

Bibliographic Details
Main Authors:	Konstantinos Kostikas, Timm Greulich, Alexander J. Mackay, Nadine S. Lossi, Maryam Aalamian-Mattheis, Xavier Nunez, Veronica A. Pagano, Francesco Patalano, Andreas Clemens, Claus F. Vogelmeier
Format:	Article
Language:	English
Published:	European Respiratory Society 2019-02-01
Series:	ERJ Open Research
Online Access:	http://openres.ersjournals.com/content/5/1/00243-2018.full

Similar Items

The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?
by: Kostikas K, et al.
Published: (2016-06-01)

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
by: Marin JM, et al.
Published: (2016-06-01)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 – a post-hoc analysis of pooled data
by: Chee-Shee Chai, et al.
Published: (2023-04-01)

FVC, but not FEV1, is associated with clinical outcomes of asthma-COPD overlap
by: Tai Joon An, et al.
Published: (2022-08-01)

A year in the life of German patients with COPD: the DACCORD observational study
by: Buhl R, et al.
Published: (2016-07-01)

A novel CT-emphysema index/FEV1 approach of phenotyping COPD to predict mortality
by: Loh LC, et al.
Published: (2018-08-01)

Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD
by: Ardak Zhumagaliyeva, et al.
Published: (2017-10-01)

A mRNA panel for differentiation between acute exacerbation or pneumonia in COPD patients
by: Wilhelm Bertrams, et al.
Published: (2024-03-01)

Genome organization and molecular characterization of the three Formica exsecta viruses—FeV1, FeV2 and FeV4
by: Kishor Dhaygude, et al.
Published: (2019-02-01)

A blood and bronchoalveolar lavage protein signature of rapid FEV1 decline in smoking-associated COPD
by: Katarina M. DiLillo, et al.
Published: (2023-05-01)

Annual decline rate in FEV1s in community-dwelling older adults diagnosed with mild to moderate COPD
by: Aldana Rosso, et al.
Published: (2022-08-01)

Cut-off value of FEV1/FEV6 as a surrogate for FEV1/FVC for detecting airway obstruction in a Korean population
by: Chung KS, et al.
Published: (2016-08-01)

Long-acting Bronchodilators in COPD Management: One or Two?
by: Konstantinos Kostikas, et al.
Published: (2023-01-01)

Evaluation of Superiority of FEV1/VC Over FEV1/FVC for Classification of Pulmonary Disorders
by: Majid Mirsadraee, et al.
Published: (2015-11-01)

Hypercoagulable State in COPD-A Comprehensive Literature Review
by: Christos Kyriakopoulos, et al.
Published: (2021-08-01)

Validation of Clinical Characteristics and Effectiveness of Pulmonary Rehabilitation in a COPD Population with Discrepancy between Exercise Tolerance and FEV1
by: Jun Horie, et al.
Published: (2021-01-01)

Clinical significance of FEV0.5 and FEV0.75 in the determination of pulmonary function in children with bronchial asthma
by: ZHENG Guimei, et al.
Published: (2023-10-01)

Machine learning for screening of at-risk, mild and moderate COPD patients at risk of FEV1 decline: results from COPDGene and SPIROMICS
by: Jennifer M. Wang, et al.
Published: (2023-04-01)

Influences of Two FEV1 Reference Equations (GLI-2012 and GIRH-2017) on Airflow Limitation Classification Among COPD Patients
by: Wei D, et al.
Published: (2022-09-01)

Allergen bronchoprovocation: correlation between FEV1 maximal percent fall and area under the FEV1 curve and impact of allergen on recovery
by: Sarah-Marie Durr, et al.
Published: (2023-01-01)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01)

Investigation of time profile of FEV1 across the onset of potential COPD: a retrospective cohort study using medical checkup data in Japan
by: Masaru Suzuki, et al.
Published: (2023-04-01)

Expediente ano 1, n. 1, fev. 1999
by: Expediente Revista de Ciências da Administração
Published: (1999-01-01)

Limitação ao fluxo aéreo em brasileiros da raça branca: VEF1/VEF6 vs. VEF1/CVF Airflow limitation in brazilian caucasians: FEV1/FEV6 vs. FEV1/FVC
by: André Luis Pinto Soares, et al.
Published: (2008-07-01)

Novel protein biomarkers for pneumonia and acute exacerbations in COPD: a pilot study
by: Anna Lena Jung, et al.
Published: (2023-06-01)

Counterpoint: Should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30% ≤ FEV1 < 50% predicted) COPD? No.
by: Pavord, I
Published: (2018)

Solid-Phase Microextraction (SPME) and Gas Chromatographic/Mass Spectrometry in Chronic Obstructive Pulmonary Disease (COPD): A Chemometric Approach
by: Loukia Lypirou, et al.
Published: (2023-10-01)

The Relationship between Physical Activity and FEV1/FVC in Asthmatics
by: Andis Putri Nawangasri, et al.
Published: (2022-02-01)

Association between 25-hydroxy vitamin D and lung function (FEV1, FVC, FEV1/FVC) in children and adults with asthma: A systematic review
by: Meryem Abi-Ayad, et al.
Published: (2023-01-01)

The Role of Digital Tools in the Timely Diagnosis and Prevention of Acute Exacerbations of COPD: A Comprehensive Review of the Literature
by: Athanasios Konstantinidis, et al.
Published: (2022-01-01)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
by: Heinrich Worth, et al.
Published: (2023-01-01)

Fev regulates hematopoietic stem cell development via ERK signaling.
by: Wang, L, et al.
Published: (2013)

The effect of age on pulmonary performance using (FEV1/FVC) % as indicator
by: Taghreed A. Hussain, et al.
Published: (2011-01-01)

Laboratory Constraints on the Neutron-Spin Coupling of feV-Scale Axions
by: Junyi Lee, et al.
Published: (2023-03-01)

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
by: Andersson Eva, et al.
Published: (2009-02-01)

Simulation and Optimization of FEV Limit Discharge’s Heat Dissipation Based on Orthogonal Experiments
by: Hong Li, et al.
Published: (2020-12-01)

FEV <sub>6</sub> as screening tool in diagnosis of obstructive airway disease
by: Aggarwal Sourabh
Published: (2010-01-01)

Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers
by: Alchanatis Manos, et al.
Published: (2011-05-01)

Author Correction: Self-perceived quality of sleep among COPD patients in Greece: the SLEPICO study
by: Nikolaos Koulouris, et al.
Published: (2022-02-01)

FEV1 Can Be Associated with Reduced Values after Vigorous Exercise in Healthy Adolescents
by: Formenti, F
Published: (2015)